IMVARIA Inc., a health tech company pioneering AI-driven digital biomarker solutions, today announced data from a study evaluating the company’s lead non-invasive digital biomarker Fibresolve showing the tool’s supplemental ability to predict mortality in patients with interstitial lung disease (ILD). The results will be presented on May 24 as an oral presentation at the Mini Symposium “Looking for the Crystal Ball: Biomarkers to Predict Disease Progression and Mortality in ILD” at the American Thoracic Society 2023 International Conference (ATS 2023) in Washington, DC.

Article written by Business Wire



Business Wire